Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Review

Hypoxia. Hypoxia, hypoxia inducible factor and myeloid cell function

Sarah R Walmsley1*, Edwin R Chilvers2 and Moira KB Whyte1

Author affiliations

1 Academic Unit of Respiratory Medicine, School of Medicine and Biomedical Sciences, University of Sheffield, Room LU104, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK

2 Respiratory Medicine Division, Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke's and Papworth Hospitals, Box157, Hills Road, Cambridge, UK, CB2 2QQ

For all author emails, please log on.

Citation and License

Arthritis Research & Therapy 2009, 11:219  doi:10.1186/ar2632

Published: 21 April 2009

Abstract

With little in the way of effective therapeutic strategies to target the innate immune response, a better understanding of the critical pathways regulating neutrophil and macrophage responses in inflammation is key to the development of novel therapies. Hypoxia inducible factor (HIF) was originally identified as a central transcriptional regulator of cellular responses to oxygen deprivation. However, the HIF signalling pathway now appears, in myeloid cells at least, to be a master regulator of both immune cell function and survival. As such, understanding the biology of HIF and its regulators may provide new approaches to myeloid-specific therapies that are urgently needed.